These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 12043057)

  • 21. Specific thrombin inhibitors ... only one tool of the antithrombotic armamentarium.
    Van De Werf F
    Eur Heart J; 1999 Apr; 20(7):479-80. PubMed ID: 10365282
    [No Abstract]   [Full Text] [Related]  

  • 22. [Acute coronary syndrome in patients using acetylsalicylic acid or warfarin].
    Vik-Mo H; Hegbom K
    Tidsskr Nor Laegeforen; 2004 Apr; 124(8):1105-6. PubMed ID: 15114389
    [No Abstract]   [Full Text] [Related]  

  • 23. Increased mortality with long-term platelet glycoprotein IIb/IIIa antagonists: an explanation?
    Vermylen J; Hoylaerts M; Arnout J
    Circulation; 2001 Nov; 104(20):E109. PubMed ID: 11705839
    [No Abstract]   [Full Text] [Related]  

  • 24. Oral platelet glycoprotein IIb/IIIa receptor antagonists: the present challenge is safety.
    Vorchheimer DA; Fuster V
    Circulation; 1998 Feb; 97(4):312-4. PubMed ID: 9468202
    [No Abstract]   [Full Text] [Related]  

  • 25. Review of antithrombotic agents used for acute coronary syndromes in renal patients.
    Fernandez JS; Sadaniantz BT; Sadaniantz A
    Am J Kidney Dis; 2003 Sep; 42(3):446-55. PubMed ID: 12955672
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Progress in the research of GPIIb/IIIa antagonists.
    Xie Z; Cao C; Feng S; Huang J; Li Z
    Future Med Chem; 2015; 7(9):1149-71. PubMed ID: 26132524
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Eptifibatide in acute coronary syndromes. Comments on the practice guidelines in antithrombotic treatment].
    Díaz de Rojas F; Ponte A; Cuenllas E
    Rev Esp Cardiol; 2000 Feb; 53(2):302-3. PubMed ID: 10734766
    [No Abstract]   [Full Text] [Related]  

  • 28. Platelet glycoprotein IIb/IIIa inhibitors in acute coronary syndromes.
    Landolfi R; De Cristofaro R
    Lancet; 2002 Jul; 360(9328):257. PubMed ID: 12133682
    [No Abstract]   [Full Text] [Related]  

  • 29. Antithrombotic therapy use after percutaneous coronary intervention and stent implantation in patients taking chronic oral anticoagulation.
    Ruiz-Nodar JM; Marín F; Lip GY
    JACC Cardiovasc Interv; 2008 Jun; 1(3):329; author reply 330-1. PubMed ID: 19463322
    [No Abstract]   [Full Text] [Related]  

  • 30. Excess dosing of antithrombotic therapy in non-ST-segment elevation acute coronary syndromes.
    Lapostolle F; Catineau J; Lapandry C; Adnet F
    JAMA; 2006 Apr; 295(16):1896-7; author reply 1897. PubMed ID: 16639043
    [No Abstract]   [Full Text] [Related]  

  • 31. Platelet glycoprotein IIb/IIIa antagonists: perioperative implications.
    Sreeram GM; Sharma AD; Slaughter TF
    J Cardiothorac Vasc Anesth; 2001 Apr; 15(2):237-40. PubMed ID: 11312488
    [No Abstract]   [Full Text] [Related]  

  • 32. Bleeding risks, risk factors and management of bleeding complications after treatment with anticoagulants, specific antithrombins, thrombolytics IIb-IIIa receptor blockers.
    Armstrong PW; Mant MJ
    Eur Heart J; 1995 Nov; 16 Suppl L():75-80. PubMed ID: 8869023
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Platelet inhibitor and oral anticoagulants. Discontinue antithrombotic drugs before colonoscopy?].
    Stiefelhagen P
    MMW Fortschr Med; 2014 Sep; 156(15):22. PubMed ID: 25282925
    [No Abstract]   [Full Text] [Related]  

  • 34. Real risks of two common drugs.
    Johns Hopkins Med Lett Health After 50; 1999 May; 11(3):3. PubMed ID: 10232088
    [No Abstract]   [Full Text] [Related]  

  • 35. IIb/IIIa or not IIb/IIIa? That is the question.
    Redwood S
    Int J Clin Pract; 1999 Dec; 53(8):577. PubMed ID: 10692749
    [No Abstract]   [Full Text] [Related]  

  • 36. Initial platelet activity may predict efficacy after chronic oral glycoprotein IIb/IIIa blockade: should we still consider uniform treatment regimens?
    Gurbel PA; McKenzie ME; Serebruany VL
    Thromb Res; 2000 Jul; 99(1):105-7. PubMed ID: 11012374
    [No Abstract]   [Full Text] [Related]  

  • 37. Transradial pharmacology: do we need access relevant dosing to maximize outcome?
    Gilchrist IC
    Catheter Cardiovasc Interv; 2011 Jan; 77(1):69-71. PubMed ID: 20518002
    [No Abstract]   [Full Text] [Related]  

  • 38. Excess dosing of antithrombotic therapy in non-ST-segment elevation acute coronary syndromes.
    Yan AT; Yan RT; Goodman SG
    JAMA; 2006 Apr; 295(16):1896; author reply 1897. PubMed ID: 16639044
    [No Abstract]   [Full Text] [Related]  

  • 39. Drug-induced thrombocytopenia in the coronary care unit.
    Patnode NM; Gandhi PJ
    J Thromb Thrombolysis; 2000 Oct; 10(2):155-67. PubMed ID: 11005938
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Anticoagulants: newer ones, mechanisms, and perioperative updates.
    Gayle JA; Kaye AD; Kaye AM; Shah R
    Anesthesiol Clin; 2010 Dec; 28(4):667-79. PubMed ID: 21074744
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.